Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Progression-Free Survival (PFS)

Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame: Baseline to disease progression or death due to any cause, assessed every 8 weeks up to 206 weeks

Duration of Response (DR)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame: Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 206 weeks

Overall Survival (OS)

Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.